Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Symposium

[Free Online Symposium] Preclinical and Clinical Development of Cell-based Immunotherapies: Translational PKPD, Safety, Biomarker, CMC, Clinical Pharmacology & Clinical Trials


Speakers: Kristen Hege (BMS); Sascha Rutz, Karen Walker (Genentech); Neehar Bhatia (Stanford University); Justine Cunningham (Sana Biotechnology); Vicki Plaks (Kite, A Gilead Company); Xiaofei Wang (FDA CBER); Weirong Wang (J&J); Yu-Waye (Wayne) Chu (Fate Therapeutics)
Organizers: Amrita Kamath, PhD, Vittal Shivva, PhD, Chunze Li, PhD, and Saileta Prabhu, PhD (Takeda)
Date: 2020-10-19- 10/20/2020
Time: 8:00-13:30 Pacific Time
Registration fee: (USD):
Location: Online via Zoom
Major Sponsor: (2)BioAgilytix Labs; Lonza Pharma & Biotech
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2020-10-18  (it will close sooner if the seating cap is reached)

About the Topic

The symposium will cover the preclinical and clinical strategies employed in the development of cell-based therapies. Topics include preclinical data package to support first in human studies, clinical pharmacology, design of early clinical trials, CMC considerations and regulatory expectations. The symposium will discuss the current strategies employed and address some of the challenges we face while advancing these therapies to patients. Additionally, topics such as biodistribution and “clearance” mechanisms, immunogenicity, translational PKPD, the relevance of preclinical models, projection of efficacious dose, etc will be addressed. Case studies will include development of CAR T-cells such as Kymriah® and Yescarta®.

Outcomes

  • Understand factors that govern cellular kinetics, dynamics, biodistribution, toxicity and immunogenicity of cell-based therapies
  • Develop a preclinical FIH package from a pharmacology/PKPD/safety/immunogenicity perspective
  • Understand manufacturing processes and challenges
  • Develop a Clinical Pharmacology Plan for cell therapies
  • Understand clinical development and regulatory strategy for cell therapies

 

AGENDA (Note: All times are in Pacific Standard Time (PST))

Day-1 (October 19th, 2020)

Theme: Preclinical Development of Cell based therapeutics

8:00 am Welcome note (Day-1)
Amrita Kamath, PhD, Director & Principal Scientist, PKPD, Genentech 

Session 1: Keynote Address

8:10 am Clinical Development of BCMA Targeted Immunotherapies in Multiple Myeloma
Speaker: Kristen Hege, MD, Senior Vice President, Early Clinical Development, BMS
Moderator: Amrita Kamath, PhD, Director & Principal Scientist, PKPD, Genentech

9:00 am. Major Sponsor Presentation - Lonza Pharma & Biotech

9:10 am. Break

Session 2: Introduction to Cell Therapy, Academic perspective and Non-Clinical and Immunogenicity Considerations
Moderator: Vittal Shivva, PhD, Scientist, PKPD, Genentech

9:30 am A Research Perspective on Cell-based Immunotherapies: concepts, considerations and challenges
Sascha Rutz, PhD, Senior Scientist, Cancer Immunology, Genentech

10:00 am Translating Cell Therapies: An Academic Perspective
Neehar Bhatia, PhD, Director, Laboratory of Cell and Gene Medicine, Stanford University 

10:30 am PharmTox Considerations for Cell Therapy: A broad overview of the Pharmacology and Safety studies to support FIH study
Justine Cunningham, PhD, Vice President, Toxicology & Biodistribution, Sana Biotechnology

11:10 am.  Break

Session 3: Case Study
Moderator: Vittal Shivva, PhD, Scientist, PKPD, Genentech

11:30 am Clinical Pharmacology and Biomarkers Associated with Clinical Outcomes Supporting Approval of YESCARTA®
Vicki Plaks, LLB, PhD, Principal Scientist, Translational Medicine, Kite, A Gilead Company

12:00 pm Panel Discussion (All Speakers) and Q&A
Moderator: Vittal Shivva, PhD, Scientist, PKPD, Genentech 

12:30 pm Wrap-up of Day-1 Sessions
Amrita Kamath, PhD, Director & Principal Scientist, PKPD, Genentech 

 

Day-2 (October 20th, 2020)

Theme: Clinical Development of Cell based therapeutics 

8:00 am Welcome note (Day-2)
Saileta Prabhu, PhD, Vice President, Clinical Biomarker Innovation & Development, Takeda 

Session 4: Keynote Address

8:05 am CMC considerations for Cell Based Therapies: Controlling Living Drugs
Speaker: Karen Walker, Senior Advisor, Cell and Gene Therapy Manufacturing, Genentech
Moderator: Saileta Prabhu, PhD, Vice President, Clinical Biomarker Innovation & Development, Takeda 

9:00 am. Major Sponsor Presentation - BioAgilytix Labs

9:10 am. Break

Session 5: Regulatory Perspectives, Clinical Pharmacology and Clinical Development Considerations
Moderator: Chunze Li, PhD, Director & Principal Scientist, Clinical Pharmacology, Genentech 

9:30 am Regulatory Perspectives on cellular therapies for Immuno-oncology indications
Xiaofei Wang, PhD, Pharmacologist, FDA CBER 

10:00 am Clinical Pharmacology Considerations for cell therapies
Weirong Wang, PhD, Scientific Director, Janssen R&D, J&J

10:30 am Clinical Development of Cell based Therapeutics
Yu-Waye (Wayne) Chu, MD, Senior Vice President, Fate Therapeutics 

11:10 am.  Break

Session 6: Considerations for Immunogenicity
Moderator: Chunze Li, PhD, Director & Principal Scientist, Clinical Pharmacology, Genentech 

11:30 am Immunogenicity of cell based therapeutics
Jim McNally, PhD, Chief Scientific Officer, BioAgilytix

Panel Discussion and Closing Remarks

12:00 pm Panel Discussion (All Speakers) and Q&A
Moderator: Chunze Li, PhD, Director & Principal Scientist, Clinical Pharmacology, Genentech 

12:30 pm Wrap-up (Day-2) & Symposium Closing remarks
Chunze Li, PhD, Director & Principal Scientist, Clinical Pharmacology, Genentech


2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Online Workshop] Career Transition for Research Scientists
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
©Pharmaceutical & BioScience Society, International; Last Modified: 3/29/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Submit a Text Ad